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Hydroxychloroquine plus standard 
of care compared with standard 
of care alone in COVID‑19: 
a meta‑analysis of randomized 
controlled trials
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The efficacy and safety of Hydroxychloroquine (HCQ) in treating coronavirus disease (COVID‑19) is 
disputed. This systematic review and meta‑analysis aimed to examine the efficacy and safety of HCQ 
in addition to standard of care (SOC) in COVID‑19. PubMed, the Cochrane Library, Embase, Web of 
sciences, and medRxiv were searched up to March 15, 2021. Clinical studies registry databases were 
also searched for identifying potential clinical trials. The references list of the key studies was reviewed 
to identify additional relevant resources. The quality of the included studies was evaluated using 
the Cochrane Collaboration tool and Jadad checklist. Meta‑analysis was performed using RevMan 
software (version 5.3). Eleven randomized controlled trials with a total number of 8161 patients were 
identified as eligible for meta‑analysis. No significant differences were observed between the two 
treatment groups in terms of negative rate of polymerase chain reaction (PCR) (Risk ratio [RR]: 0.99, 
95% confidence interval (CI) 0.90, 1.08; P = 0.76), PCR negative conversion time (Mean difference 
[MD]: − 1.06, 95% CI − 3.10, 0.97; P = 0.30), all‑cause mortality (RR: 1.09, 95% CI 1.00, 1.20; P = 0.06), 
body temperature recovery time (MD: − 0.64, 95% CI − 1.37, 0.10; P = 0.09), length of hospital stay 
(MD: − 0.17, 95% CI − 0.80, 0.46; P = 0.59), use of mechanical ventilation (RR: 1.12, 95% CI 0.95, 
1.32; P = 0.19), and disease progression (RR = 0.82, 95% CI 0.37, 1.85; P = 0.64). However, there was 
a significant difference between two groups regarding adverse events (RR: 1.81, 95% CI 1.36, 2.42; 
P < 0.05). The findings suggest that the addition of HCQ to SOC has no benefit in the treatment of 
hospitalized patients with COVID‑19. Additionally, it is associated with more adverse events.
The COVID-19 pandemic was identified and reported for the first time in Wuhan,  China1–3, and has been rec-
ognized as a global public health concern by the World Health Organization (WHO)4. The mortality of critically 
ill patients with COVID-19 is  considerable5. The initial estimations for the case fatality rate were about 2.3% 
in  China6 and 7.2% in  Italy7. The 2019-nCoV infection causes clusters of severe respiratory illnesses similar to 
severe acute respiratory syndrome (SARS) coronavirus and, in severe cases, is associated with hospitalization, 
ICU admission, and frequent  mortalities8, 9. Fever, coughing, shortness of breath, muscle ache, confusion, head-
ache, sore throat, rhinorrhea, chest pain, diarrhea, nausea, and vomiting are among the clinical manifestations 
of the  disease10. Early efforts have focused on describing the clinical course, containing severe cases, and treating 
the  sick11.
There are several options for controlling and preventing the development of COVID-19 infections, including 
vaccines, monoclonal antibodies, oligonucleotide-based therapies, peptides, interferon therapies, and small-
molecule  drugs5. Lopinavir/Ritonavir (400/100 mg every 12 h), Chloroquine (500 mg every 12 h), and Hydroxy-
chloroquine (HCQ) (200 mg every 12 h) and Alpha-interferon are also proposed as courses of  treatment12.
HCQ is used for a variety of diseases, including  IgAN13, 14,  Arthritis15, 16, Pulmonary  Sarcoidosis17, Cutane-
ous lupus  erythematosus18–20, Sjogren’s  syndrome21, and Type 2 diabetes  mellitus22. HCQ prevents the activity of 
lysosomal enzymes. This drug can reduce the production of cytokines, including type 1 interferons, and inhibit 
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T cell activation and the differentiation and expression of excitatory molecules (CD154)23. Currently, several 
 observational24, 25 and clinical  studies26, 27 have evaluated the efficacy of HCQ on COVID-19. Besides, several 
meta-analyses examined HCQ in COVID-19 regarding a few of the outcomes, such as mortality and negative 
rate of polymerase chain reaction (PCR). Therefore, there is an urgent need to examine more detailed outcomes 
based on the available evidence. The purpose of this study was to examine whether HCQ in addition to standard 
of care (SOC) versus SOC alone is more effective and safer in hospitalized patients with COVID-19.
Methods
The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) 
with the registration number CRD42020179425. When writing this report, we used the preferred reporting items 
for systematic reviews and meta-analysis (PRISMA)28. The PRISMA statement consists of a 27-item checklist 
and a 4-phase flow diagram. We used the PRISMA checklist to prepare the report and diagram for the screening 
process.
Search strategy. A systematic review of the relevant literature was conducted in PubMed, The Cochrane 
Library, Embase, Web of Sciences, and medRxiv up to March 15, 2021. In order to increase the sensitivity of the 
search, Google Scholar was also searched. In addition, the European Union Clinical Trials Register, Clinical trial 
Gov. and Chinese Clinical Trial Registry (ChiCTR) were searched. Finally, the references list of the final studies 
and review articles were reviewed for more citations. The search terms used were 2019-nCoV, SARS-CoV-2, 
COVID-19, and Hydroxychloroquine, which were usually limited to the title and the abstract of the articles. We 
included articles with English full-text or abstract.
The following is our search strategy used to search for relevant articles published in PubMed: 
((((((COVID-19[Title/Abstract]) OR (SARS-CoV-2[Title/Abstract])) OR (Coronavirus[Title/Abstract])) OR 
(Coronavirus[MeSH Terms])) OR (2019-nCoV[Title/Abstract])) OR (Novel coronavirus[Title/Abstract])) AND 
(Hydroxychloroquine[Title/Abstract]). We followed a similar logic while performing searches in other databases.
Study selection. Two researchers independently screened the identified studies based on the inclusion cri-
teria. Disagreements were resolved by discussion among the authors. The following inclusion criteria were used 
for selecting the articles: (1) hospitalized patients with suspected or confirmed COVID-19 by laboratory tests; 
(2) HCQ plus SOC as intervention; (3) SOC alone as control; (4) randomized controlled trial as study design; 
(5) published as abstract or full-text; and (6) primary and secondary outcomes of interests (negative conver-
sion time, negative rate of PCR, mortality rate, body temperature recovery time, length of hospital stay, and any 
adverse events). Other studies and reports such as letters to the editor, case reports, editorial comments, obser-
vational studies, and animal models were excluded.
Data extraction and quality assessment. The Cochrane risk of bias tool was used to assess the risk of 
bias in five domains (selection, performance, attrition, reporting, and other) in the included studies. We used 
the Jadad checklist to evaluate the quality of clinical trial studies. Information on the study characteristics (place, 
design, and duration); patient’s characteristics (age, sex, and the number of patients); intervention and control 
(treatment protocol); efficacy outcomes; and adverse events were extracted. Both processes were independently 
performed by two authors, and disagreements were resolved by discussion among the authors.
Quantitative data synthesis. A meta-analysis was conducted to compare the efficacy and safety of HCQ 
plus SOC versus SOC alone using the RevMan (version 5.3) software which is recommended by the Cochrane 
Handbook for Systematic Reviews of Interventions. The mean difference (MD) and risk ratio (RR) with a 95% 
confidence interval (CI) were used for continuous and dichotomous variables, respectively. Statistical heteroge-
neity was evaluated using I-square > 50% and Chi-square with a significance level p < 0.1. The random-effects 
method was used for statistical heterogeneity; otherwise, the fixed-effect method was used.
Results
Study characteristics. Figure 1 shows the process of literature search, removal of duplication, and screen-
ing. Of the total 1,205 records, 1,098 were excluded based on the title and abstract. The remaining 107 records 
were review for full text. Finally, eleven randomized controlled trials (RCTs)26, 29–38 with 8161 patients were 
included in the meta-analysis. The main characteristics of the selected studies are presented in Table 1. Assess-
ment of the risk of bias using the Cochrane Collaboration tool is presented in Fig. 2.  
Outcomes. Primary outcomes. The meta-analysis demonstrated that there was no significant difference 
between the HCQ plus SOC group and SOC group in terms of the negative rate of PCR (RR: 0.99, 95% CI 0.90, 
1.08; P = 0.76), PCR negative conversion time (MD: − 1.06, 95% CI − 3.10, 0.97; P = 0.30), and all-cause mortality 
(RR: 1.13, 95% CI 0.99 1.27, P = 0.06) (Fig. 3).
Secondary outcomes. The pooled RR of included studies showed that adding HCQ to SOC was not associ-
ated with significant effect on secondary outcomes including body temperature recovery time (MD: −  0.64, 
95% CI − 1.37, 0.10; P = 0.09), the length of hospital stay (MD: − 0.17, 95% CI − 0.80 0.46, P = 0.59), the use of 
mechanical ventilation (RR: 1.12, 95% CI 0.95, 1.32; P = 0.19), and disease progression (RR: 0.82, 95% CI 0.37, 
1.85; P = 0.64) (Fig. 3). The pooled RR of 5 studies showed that the addition of HCQ to SOC was associated with 
higher rates of adverse events in hospitalized patients (RR: 1.81, 95% CI 1.36, 2.42; P < 0.05) (Fig. 4). However, 
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there was no significant difference between the two groups in terms of serious adverse events (RR: 1.29, 95% CI 
0.50, 3.30; P = 0.60) (Fig. 4).
Sensitivity analysis and subgroup analysis. The findings of the subgroup analysis are presented in 
Table  2. The findings showed that primary outcomes did not change regarding dose, sample size, treatment 
duration, and severity of COVID-19. We performed a sensitivity analysis based on different settings and control 
groups. For this reason, we included RCTs done on non-hospitalized patients and RCTs with placebo as control. 
The result did not change in terms of the negative rate of PCR and mortality rate (Table 2).
Discussion
The purpose of this study was to examine the efficacy and safety of HCQ plus SOC compared to SOC alone for 
COVID-19.
Several RCTs have examined the efficacy and safety of HCQ in treating COVID-19. The findings of our meta-
analysis showed that the addition of HCQ to SOC in patients with COVID-19 was not associated with significant 
improvement in any outcomes reported in patients. Previously published meta-analyses39–42 on observational 
studies and RCTs also found no clinical benefits for HCQ in comparison with SOC for COVID-19 patients, which 
confirms our findings. Gautret et al.43 suggested that the causes of insufficient response to treatment with HCQ in 
the non-respondents with COVID-19 should be examined by factors such as SARS-CoV-2 strains, genome, and 
other associated factors with the metabolism of HCQ in patients. A possible mechanism for HCQ inefficiency 
was explained by Sandeep and  McGregor44 using virtualized quantum mechanical modeling. However, Yao et al.45 
found that HCQ was more potent than Chloroquine in inhabiting SARS-CoV-2 in vitro.
It should be noted that most of the included studies in these meta-analyses were observational. There are 
some concerns regarding the limitations of these studies that should be considered. All kinds of biases such as 
confounding, reverse causation, statistical considerations, and other issues are limitations of these studies in 
the estimation of drug efficacy and  safety46. The Agency for Healthcare Research and Quality (AHRQ) has pro-
vided recommendations on including observational studies in the comparative effectiveness review process for 
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Figure 1.  Flowchart of the study selection process.
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comparing medical  interventions30. Our meta-analysis showed that HCQ was not associated with a significant 
reduction or increase in the COVID-19 mortality rate. The results from similar meta-analyses40, 47 are in line with 
our findings. Moreover, we conducted a sensitivity analysis of studies done in nonhospital patients and placebo 
as a control, plus included RCTs regarding the negative rate of PCR and mortality rate. The result did not show 
any significant differences. Fiolet et al.47 also found that HCQ was not associated with a different mortality rate 
in all studies and RCTs, which confirms our findings.
Some  studies43, 48 have supported the synergistic effect of HCQ with Azithromycin on COVID-19. In an 
open-label non-randomized clinical trial, Gautret et al.43 found that 100% of patients who received HCQ and 
Azithromycin as combination therapy successfully recovered from COVID-19. These authors found similar 
results in another study. A meta-analysis showed that HCQ alone or in combination with Azithromycin in com-
parison with the control group was not effective in treating COVID-19 and was associated with higher mortality 
rates. It seems that there is no benefit for HCQ in combination with Azithromycin, and it is associated with an 
increased mortality  rate47. Contradictorily, a study on 1,438 patients hospitalized with Covid-19 in all United 
States Veterans Health Administration medical centers found that the rates of death in patients under treatment 
with HCQ alone were higher than and HCQ plus Azithromycin (27.8%, 22.1%)25. However, a meta-analysis of the 
adverse effects of long-term Azithromycin use in patients with chronic lung diseases showed that Azithromycin 
is associated with an increased risk of bacterial resistance (2.7-fold)49.
Our meta-analysis showed that as an add-on therapy to SOC was associated with more adverse events. 
Reported adverse events in RCTs were mainly mild. Three RCTs reported serious adverse events in patients 
taking HCQ and SOC. However, this difference was not statistically significant. Generally, adverse effects of 
antimalarial are usually rare and  mild50. Gastric symptoms are a prevalent adverse effect of  HCQ51, 52; other 
adverse events include  Cutaneous53,  headache54–56,  Cardiomyopathy57–59, and  Retinopathy60–64. Regarding the 
short-term follow-up of the studies, it is recommended that patients who received HCQ should be monitored 
for possible adverse events over a longer period of time.
Limitations. High heterogeneity between studies, the use of different treatment protocols as SOC, short 
follow-up periods, and lack of rigorous methodologies of the studies were among the limitations of our study. 
Nevertheless, the findings of this study can be beneficial for guiding clinicians in decisions regarding COVID-19 
treatment.
Table 1.  The characteristics of RCTs included in the meta-analysis. CT: Computed tomography, HCQ: 
Hydroxychloroquine, NR: Not reported, PCR: Polymerase chain reaction, RT-PCR: Reverse transcription 
polymerase chain reaction.
Author, year Place Patients (N, male) Age Diagnosis Intervention (N, HCQ protocol) SOC (N, protocol) Jadad scale
Abd-Elsalam, 2020 Egypt 194,118 40.72 PCR
97; 400 mg twice/day (in day 1) 
followed by 200 mg tablets twice/
day + SOC
97; Paracetamol, oxygen, fluids, 
empiric antibiotic, oseltamivir, 
and invasive mechanical ventila-
tion
3
Chen Z, 2020 China 62, 29 44.7 RT-PCR 31; (400 mg/day (200 mg/bid) between days 1 and 5) + SOC




Chen J, 2020 China 30, 21 48.6 PCR 15; (400 mg per day for 5 days) + SOC
15; O2 therapy, interferon, lopi-
navir/ ritonavir, antibiotics, and 
supportive treatment
2
Chen CP, 2020 Taiwan 33, 19 32.9 RT-PCR
21; HCQ 400 mg twice for 1 day 
and HCQ 200 mg twice daily for 
6 days + SOC




Chen L, 2020 China 66, 15 NR RT-PCR or CT 18; 200 mg Bid for 10 days 12; NR 3
Cavalcanti, 2020 Brazil 504, 265 50.3 NR 221; HCQ 400 mg twice daily, for 7 days + SOC
227; Glucocorticoids, immu-
nomodulators, antibiotic and 
antiviral agents
4
Kamran, 2020 Pakistan 500,466 35.96 PCR
349; HCQ 400 mg twice a day for 
day one followed by 200 mg 12 
hourly for next 5 days + SOC
151; Vit C, zinc, Vit-D, Paraceta-
mol, intravenous fluids, hemody-
namic monitoring parameters
3
Lyngbakken, 2020 Norway 53, 35 62 RT-PCR 27; HCQ 400 mg twice for 7 days + SOC 26; NR 2
RC Group,2020 UK 4716, 2935 NR NR
1561; 800 mg at 0 and 6 h; 
400 mg at 12 h; 400 mg × 9 
days + SOC
3155; NR 2
Tang, 2020 China 150, 82 46 Real timeRT-PCR
75; HCQ 1200 mg/day × 3  day 
followed by 800/day + SOC
75; Intravenous fluids, supple-
mental oxygen, , hemodynamic 
monitoring, and intensive care
3
WHO Solidarity Trial, 2021 30 Countries 1853,1109 NR NR
947,800 mg at 0 and hour 6, 
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Conclusion
According to the findings of this study, HCQ in addition to SOC appears to be not an effective treatment in 
primary outcomes, including negative conversion time, the negative rate of PCR, and mortality rate. In addi-
tion, HCQ did not show a significant improvement in other secondary outcomes. HCQ was also associated with 
higher rates of adverse events.
Figure 2.  Risk of bias in the selected studies.
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Figure 3.  Forest plot of HCQ plus SOC vs. SOC for primary outcomes; Negative conversion time (A), Negative 
rate of PCR (B), and All-cause mortality (C) in COVID-19 patients.
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Figure 4.  Forest plot of HCQ plus SOC vs. SOC for primary outcomes; Body temperature recovery time (A), 
Mechanical ventilation (B), Hospital stay (C), Disease progression (D), Any adverse event (E), and Serious 
adverse events (F) in COVID-19 patients.
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